SCORPIO-PEP is the first and only Phase 3 study of a COVID-19 oral antiviral as a post-exposure prophylaxis to meet the primary endpoint of preventing COVID-19. * The study met both the primary ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback